📊 ACUT Key Takeaways
Is Accustem Sciences Inc. (ACUT) a Good Investment?
Accustem Sciences is in severe financial distress with negative stockholders' equity of -$2.9M, indicating the company is technically insolvent. The company is burning cash at an unsustainable rate (-$883.7K free cash flow) with only $14.4K in cash reserves against $4.5M in liabilities. With zero revenue, no viable path to profitability, and complete lack of operating metrics, the company faces imminent financial collapse.
Accustem Sciences shows extremely weak fundamentals: it has no reported revenue, continues to generate operating and net losses, and is consuming cash without an evident self-funding business model. Financial health is highly stressed, with minimal cash, a sub-1.0 current ratio, and deeply negative equity, which together point to elevated dilution, financing, and going-concern risk unless the company can establish durable commercial revenue.
Why Buy Accustem Sciences Inc. Stock? ACUT Key Strengths
- No strengths identified
- EPS loss improved year over year, indicating some reduction in per-share loss pressure
- Net loss appears stable rather than rapidly deteriorating, suggesting expense growth is not currently accelerating
- Capital expenditure needs are low, which limits cash demands from fixed-asset investment
ACUT Stock Risks: Accustem Sciences Inc. Investment Risks
- Negative stockholders' equity of -$2.9M indicates insolvency
- Critically low cash balance of $14.4K with $4.5M in liabilities
- No revenue generation; company is pre-revenue or revenue-less
- Negative free cash flow of -$883.7K burning through minimal cash reserves
- Current ratio of 0.35x indicates severe liquidity crisis and inability to meet short-term obligations
- No insider activity or buying support in last 90 days
- Operating losses of -$1.2M with no offsetting revenue
- Negative ROA of -78.9% indicates catastrophic asset inefficiency
- No reported revenue means the business currently lacks demonstrated operating traction
- Negative stockholders equity and a 0.35x current ratio indicate severe balance-sheet and liquidity weakness
- Very low cash balance relative to ongoing operating cash burn creates high refinancing or dilution risk
Key Metrics to Watch
- Cash burn rate and runway to insolvency
- Revenue inception and pathway to profitability
- Debt restructuring or equity injection announcements
- Changes in stockholders' equity trajectory
- Revenue generation and commercialization progress
- Cash runway including quarterly operating cash burn and financing needs
Accustem Sciences Inc. (ACUT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
ACUT Profit Margin, ROE & Profitability Analysis
ACUT vs Healthcare Sector: How Accustem Sciences Inc. Compares
How Accustem Sciences Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Accustem Sciences Inc. Stock Overvalued? ACUT Valuation Analysis 2026
Based on fundamental analysis, Accustem Sciences Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Accustem Sciences Inc. Balance Sheet: ACUT Debt, Cash & Liquidity
ACUT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Accustem Sciences Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.13 indicates the company is currently unprofitable.
ACUT Revenue Growth, EPS Growth & YoY Performance
Accustem Sciences Inc. Dividends, Buybacks & Capital Allocation
ACUT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Accustem Sciences Inc. (CIK: 0001850767)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ACUT
What is the AI rating for ACUT?
Accustem Sciences Inc. (ACUT) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 95% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ACUT's key strengths?
Claude: . ChatGPT: EPS loss improved year over year, indicating some reduction in per-share loss pressure. Net loss appears stable rather than rapidly deteriorating, suggesting expense growth is not currently accelerating.
What are the risks of investing in ACUT?
Claude: Negative stockholders' equity of -$2.9M indicates insolvency. Critically low cash balance of $14.4K with $4.5M in liabilities. ChatGPT: No reported revenue means the business currently lacks demonstrated operating traction. Negative stockholders equity and a 0.35x current ratio indicate severe balance-sheet and liquidity weakness.
What is ACUT's revenue and growth?
Accustem Sciences Inc. reported revenue of N/A.
Does ACUT pay dividends?
Accustem Sciences Inc. does not currently pay dividends.
Where can I find ACUT SEC filings?
Official SEC filings for Accustem Sciences Inc. (CIK: 0001850767) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ACUT's EPS?
Accustem Sciences Inc. has a diluted EPS of $-0.08.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ACUT a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Accustem Sciences Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ACUT stock overvalued or undervalued?
Valuation metrics for ACUT: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ACUT stock in 2026?
Our dual AI analysis gives Accustem Sciences Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ACUT's free cash flow?
Accustem Sciences Inc.'s operating cash flow is $-872.7K, with capital expenditures of $11.0K.
How does ACUT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 0.35 (avg: 2).